Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Rupe

Surgery Salina, KS Medical Doctor

NPI 1740401249 CMS profile 170707

737 E Crawford St, Salina, KS 67401

Open in the dashboard

General payments

$4,393

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Rupe of Salina, KS is reported in the CMS Open Payments database as having received $4,393 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $181 8
2024 General $2,737 13
2023 General $166 8
2022 General $562 10
2021 General $132 8
2020 General $533 9
2019 General $81 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Rupe
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Christopher Rupe were reported at $181. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Christopher Rupe Surgery median Middle half National median
2019 $81 $253 $82–$1,521 $163
2020 $533 $131 $40–$706 $114
2021 $132 $168 $50–$904 $132
2022 $562 $224 $76–$1,218 $149
2023 $166 $253 $82–$1,255 $160
2024 $2,737 $279 $90–$1,381 $164
2025 $181 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $2,483 6 payments
  2. Bard Peripheral Vascular, Inc. $417 4 payments
  3. Endologix, Inc. $313 1 payment
  4. LeMaitre Vascular, Inc. $238 10 payments
  5. Smith+Nephew, Inc. $207 10 payments
  6. Inari Medical, Inc. $124 1 payment
  7. Stryker Corporation $76 2 payments
  8. Davol Inc. $73 2 payments
  9. Myriad Genetic Laboratories, Inc. $56 4 payments
  10. Zimmer Biomet Holdings, Inc. $38 1 payment
  11. Other $369 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,104 55 payments
  2. Education $1,500 1 payment
  3. Travel and Lodging $781 3 payments
  4. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. DAVINCI XI $1,500 1 payment
  2. Da Vinci Surgical System $983 5 payments
  3. ARTEGRAFT VASCULAR GRAFT $226 9 payments
  4. FLOWTRIEVER CATHETER, S $155 2 payments
  5. CT THROMBECTOMY SYSTEM KIT $155 2 payments
  6. GRAFIX PL Other Advanced Wound Management $97 5 payments
  7. Stravix $64 3 payments
  8. STRAVIX PL $61 3 payments
  9. GRAFIX PL Other Advanced Wound Management $58 3 payments
  10. SPY TECHNOLOGY $46 1 payment
  11. Other $803 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

475

Median for General Surgery: 59

Drug cost

$34,786

Median for General Surgery: $393

Branded share of claims

49.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 49 $31,805
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 123 $743
Anastrozole Generic 38 $524
Tamoxifen Citrate Generic 31 $514
Clopidogrel Clopidogrel Bisulfate Brand 54 $386
Doxycycline Hyclate Generic 19 $266
Oxycodone Hcl Generic 15 $95
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $93
Tramadol Hcl Generic 60 $83
Cephalexin Generic 18 $76

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 300 billing codes

Paid by Medicare

$374,645

Medicare's payments for the services billed

Medicare patients

742

Average age 73

Services billed

3,051

392 women, 350 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 41%
Arthritis 41%
Chronic kidney disease 38%
Ischemic heart disease 28%
Depression 26%
Cancer 24%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record